Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 650 across all filing types
Latest filing 2023-08-29 Major Shareholding Noti…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the shareholding status, changes in ownership, and contractual relationships (such as pledges and loans) of major shareholders. This falls under the 'Major Shareholding Notification' category.
2023-08-29 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Agreement' involving a change in the largest shareholder. This type of filing, which discloses financial arrangements, collateral, and debt obligations of the major shareholder, is a standard regulatory disclosure in the Korean market (DART system). Since it does not fit into specific categories like Earnings Release, Annual Report, or M&A, it falls under the 'Regulatory Filings' category.
2023-08-25 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a regulatory filing required under the Capital Markets Act in South Korea when a person or entity acquires a significant stake (typically 5% or more) in a listed company. This document details the shareholding status, changes in ownership, and contractual relationships (such as pledges and loans) of the major shareholders of GemVax & Kael. It is a standard regulatory disclosure form, not an annual report, earnings release, or announcement of a report.
2023-08-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is a standard regulatory requirement for directors and major shareholders to disclose changes in their shareholdings, which falls under the 'Director's Dealing' category.
2023-08-22 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities. This type of filing is specifically used to report insider transactions or changes in shareholding by major shareholders and executives. According to the provided definitions, 'Director's Dealing' (DIRS) covers reports of personal share transactions by company directors and executives, and 'Major Shareholding Notification' (MRQ) covers changes in significant share ownership. Given the document explicitly identifies the reporter as a '10% or more shareholder' (10%이상주주) and details a change in their holdings, it fits the criteria for a Major Shareholding Notification.
2023-08-22 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing from a Korean company (GemVax) detailing a 'Correction Report' regarding a 'Stock Collateral Agreement' involving the company's largest shareholder. It provides specific details on collateralized shares, debt amounts, and creditor information. This type of disclosure regarding changes in share ownership structure and collateralization is classified as a regulatory filing under the RNS category, as it does not fit into specific categories like M&A, dividends, or earnings releases.
2023-08-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.